16.09.2021 10:30

Sartorius to Open New Application and Service Hub in Shanghai

Folgen
Werbung

-  Supporting Chinese customers with cutting-edge innovations to accelerate technological breakthroughs in life science research and biopharma processing

-  Significantly extended capabilities in biological drug discovery, process development, testing and validation to meeting growing local customer demand

-  Continuous increase in investments and long-term commitment in China

SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- The life science group Sartorius officially opened its new, significantly expanded Application and Service Hub in Zhangjiang Science City in Shanghai, China. Equipped with the latest innovative instrumentation and offering cutting-edge professional expertise, this Hub covering over 3,000 square meters accommodates the Sartorius Application Center 3.0, the Confidence® Validation Services Laboratory 2.0 and APAC Service Hub. This combined facility is designed as an integrated solution platform to empower and accelerate progress in areas ranging from research to process development to production in the Chinese life sciences and biopharmaceutical industries. "The grand opening of the Application and Service Hub marks a further milestone in Sartorius' development in China and underlines its long-term commitment to this fast-growing market," said Sarah Wang, Head of Sales and Services in China.

 

Sartorius Logo

 

Given the fast growth of the Chinese biopharmaceutical industry over the past years, Sartorius has been continuously investing to broaden its footprint and expanding its capacity in China to meet the growing needs of local customers. The latest innovations in bioanalytic, continuous processing and digitalization are now going live in the upgraded Application Center 3.0, where the new Sartorius process solutions will be showcased and experienced as their first point of entry. More importantly, early stage monoclonal antibody (mAb) and virus-based therapies can be discovered, and their process applications can be custom developed, tested, and verified. With help of intelligent digital systems, process data could be monitored and controlled with remote SCADA system, and deviations can be reliably detected and analyzed in real time to drive the best possible outcomes. These systems combined with the power of local Sartorius expertise will enable customers to benefit from more efficient and productive process solutions for their specific products, lowering their investment outlay and significantly reducing the time to market.

In life science research and the biopharma industry, it is important not only to speed up the entire process chain from drug discovery to commercial-scale production, but also to ensure that each process step is robust and safe as well as complies with applicable GMP and GLP regulatory requirements. With its capacity and capabilities expanded, the new Sartorius China Confidence® Validation Services Laboratory 2.0 will enable customers to overcome validation-related challenges. The Sartorius Hub's sterile filter validation facility will double its capacity by 2022 to meet increasing local demand. Extractables and Leachables (E&L) testing and virus clearance studies are the new local capabilities, helping to ensure regulatory compliance and safe implementation of single-use systems in biopharmaceutical production and reliable clearance processes to guarantee patient safety.

The new Sartorius APAC Service Hub ensures professional after-sales continuity for equipment repair, maintenance, and calibration service. As it is crucial for production-scale equipment to function correctly in customers' bioprocesses and this usually entails significant investments, Sartorius has expanded its Service Hub to provide real-equipment-based training, not only for Sartorius engineers in Asia but also for its customers' engineers to prevent malfunctions before they happen and to extend the service life of Sartorius equipment. Professional service engineers and a complete range of spare parts on stock speed up calibration, repair and maintenance of smaller-scale instruments significantly.

Sartorius is investing increasingly in local capacity expansion and customer-centric services. The newly opened Customer Interaction Center in Beijing for testing, validating, and adjusting equipment functionalities has successfully completed its first large-scale customer project. Moreover, the Sartorius Laboratory and Service Center in YETDA Biopark in Yantai, China, is under construction. As of the first half of 2022, this facility will provide timely, on-site support to our customers and biotech startups in their drug discovery and early development phases. Sartorius currently employs more than 700 team members in China and is continuously expanding its local organization.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Follow Sartorius on Twitter and on LinkedIn.

Contact
Petra Kirchhoff                                                                    
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686                                                                         
petra.kirchhoff@sartorius.com

Logo - https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/sartorius-to-open-new-application-and-service-hub-in-shanghai-301377427.html

SOURCE Sartorius AG

Nachrichten zu Sartorius AG Vz.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Sartorius AG Vz.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
13:31 UhrSartorius vz HaltenNorddeutsche Landesbank (Nord/LB)
21.10.2021Sartorius vz SellUBS AG
21.10.2021Sartorius vz BuyWarburg Research
21.10.2021Sartorius vz OverweightJP Morgan Chase & Co.
20.10.2021Sartorius vz BuyKepler Cheuvreux
21.10.2021Sartorius vz BuyWarburg Research
21.10.2021Sartorius vz OverweightJP Morgan Chase & Co.
20.10.2021Sartorius vz BuyKepler Cheuvreux
20.10.2021Sartorius vz BuyWarburg Research
20.10.2021Sartorius vz OverweightJP Morgan Chase & Co.
13:31 UhrSartorius vz HaltenNorddeutsche Landesbank (Nord/LB)
20.10.2021Sartorius vz HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
20.09.2021Sartorius vz HaltenDZ BANK
29.07.2021Sartorius vz HaltenDZ BANK
28.07.2021Sartorius vz HaltenNorddeutsche Landesbank (Nord/LB)
21.10.2021Sartorius vz SellUBS AG
20.10.2021Sartorius vz SellUBS AG
27.07.2021Sartorius vz SellUBS AG
21.07.2021Sartorius vz SellUBS AG
07.07.2021Sartorius vz SellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sartorius AG Vz. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

DAX geht fester in den Feierabend -- Hertz bestellt 100.000 Teslas -- ifo-Index sinkt -- Finanzinvestoren wollen zooplus gemeinsam übernehmen -- HSBC, BASF, Deutsche Bank im Fokus

Moderna: Corona-Impfung bei Kindern mit 'robuster Wirkung'. Microsoft warnt vor weiteren Hackerangriffen. Daimler Truck erhält Straßenzulassung für Brennstoffzellen-Lkw. PayPal: Verfolgen derzeit nicht den Kauf von Pinterest. FUCHS PETROLUB-Aufsichtsratschef Bock gibt 2022 sein Amt auf. Italien blockiert offenbar Verisem-Übernahme durch Syngenta.

Umfrage

Würden Sie eine verpflichtende Corona-Impfung gutheißen?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln